Compare GDC & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDC | STXS |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.3M | 201.6M |
| IPO Year | N/A | 2004 |
| Metric | GDC | STXS |
|---|---|---|
| Price | $2.76 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 35.5K | ★ 401.3K |
| Earning Date | 05-14-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,346,617.00 |
| Revenue This Year | N/A | $34.08 |
| Revenue Next Year | N/A | $35.18 |
| P/E Ratio | $7.47 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.93 | $1.54 |
| 52 Week High | $9.92 | $3.59 |
| Indicator | GDC | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 37.11 |
| Support Level | $2.32 | $1.74 |
| Resistance Level | $3.72 | $2.52 |
| Average True Range (ATR) | 0.28 | 0.10 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 14.97 | 12.50 |
GD Culture Group Ltd focuses its business on two segments mainly through the Company and two subsidiaries. 1) AI-driven digital human creation and customization; 2) Live streaming and e-commerce. The company has relentlessly been focusing on serving its customers and creating value for them through the continual innovation and optimization of its products and services. For the AI-driven digital human creation and customization sector, the Company uses AI algorithms and software to generate realistic 3D or 2D digital human models. AI algorithms and machine learning models are used to simulate human characteristics, such as facial expressions, body movements, and even speech patterns.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.